| Primary |
| Drug Use For Unknown Indication |
38.8% |
| Product Used For Unknown Indication |
14.8% |
| Bronchitis |
8.5% |
| Prophylaxis |
3.9% |
| Erysipelas |
3.5% |
| Sinusitis |
3.4% |
| Pneumonia |
3.2% |
| Hypertension |
2.9% |
| Tonsillitis |
2.4% |
| Upper Respiratory Tract Infection |
2.4% |
| Lung Disorder |
2.2% |
| Tooth Abscess |
2.0% |
| Urinary Tract Infection |
2.0% |
| Toothache |
1.8% |
| Cough |
1.6% |
| Pain |
1.6% |
| Hiv Infection |
1.4% |
| Postoperative Care |
1.3% |
| Infection |
1.1% |
| Anaesthesia |
1.0% |
|
| Urticaria |
12.9% |
| Vomiting |
12.5% |
| Pruritus |
11.8% |
| Rash |
8.1% |
| Jaundice |
5.9% |
| Toxic Skin Eruption |
5.5% |
| Pyrexia |
5.1% |
| Renal Failure Acute |
4.8% |
| Rash Maculo-papular |
4.0% |
| Weight Decreased |
4.0% |
| Toxic Epidermal Necrolysis |
3.7% |
| Thrombocytopenia |
2.9% |
| Liver Function Test Abnormal |
2.6% |
| Malaise |
2.6% |
| Renal Failure |
2.6% |
| Drug-induced Liver Injury |
2.2% |
| Hepatitis |
2.2% |
| Liver Injury |
2.2% |
| Pancytopenia |
2.2% |
| Product Quality Issue |
2.2% |
|
| Secondary |
| Product Used For Unknown Indication |
34.3% |
| Drug Use For Unknown Indication |
10.3% |
| Lung Disorder |
7.5% |
| Pneumonia |
4.6% |
| Hypertension |
4.3% |
| Pain |
4.3% |
| Nosocomial Infection |
3.7% |
| Prophylaxis |
3.3% |
| Pyrexia |
3.0% |
| Infection |
2.8% |
| Bronchitis |
2.7% |
| Sinusitis |
2.6% |
| Anaesthesia |
2.6% |
| Urinary Tract Infection |
2.5% |
| Depression |
2.4% |
| Hiv Infection |
2.3% |
| Atrial Fibrillation |
2.1% |
| Ear Infection |
1.8% |
| Cough |
1.5% |
| Erysipelas |
1.5% |
|
| Drug Hypersensitivity |
20.8% |
| Thrombocytopenia |
6.9% |
| Toxic Skin Eruption |
6.9% |
| Vomiting |
6.6% |
| Hepatocellular Injury |
5.7% |
| Weight Decreased |
5.1% |
| Pyrexia |
4.2% |
| Rash |
4.2% |
| Urticaria |
4.2% |
| Hepatitis Cholestatic |
3.9% |
| Renal Failure Acute |
3.9% |
| Rash Maculo-papular |
3.6% |
| Skin Exfoliation |
3.6% |
| Respiratory Disorder |
3.3% |
| Jaundice |
3.0% |
| Tremor |
3.0% |
| Cholestasis |
2.7% |
| Neutropenia |
2.7% |
| Renal Failure |
2.7% |
| Toxic Epidermal Necrolysis |
2.7% |
|
| Concomitant |
| Drug Use For Unknown Indication |
27.1% |
| Product Used For Unknown Indication |
25.4% |
| Pain |
6.0% |
| Diffuse Large B-cell Lymphoma |
5.9% |
| Hypertension |
4.3% |
| Prophylaxis |
3.4% |
| Crohn's Disease |
2.9% |
| Rheumatoid Arthritis |
2.6% |
| Depression |
2.3% |
| Asthma |
2.2% |
| Multiple Myeloma |
2.2% |
| Nausea |
2.2% |
| Constipation |
2.0% |
| Bronchitis |
1.9% |
| Pneumonia |
1.9% |
| Contraception |
1.6% |
| Non-small Cell Lung Cancer |
1.6% |
| Urinary Tract Infection |
1.6% |
| Hiv Infection |
1.4% |
| Anxiety |
1.4% |
|
| Vomiting |
12.3% |
| Pulmonary Embolism |
9.2% |
| Pyrexia |
8.2% |
| Weight Decreased |
8.0% |
| Thrombocytopenia |
6.8% |
| Pain |
5.6% |
| Urinary Tract Infection |
5.6% |
| Pneumonia |
5.1% |
| Sepsis |
4.4% |
| Respiratory Failure |
4.3% |
| Septic Shock |
3.9% |
| Weight Increased |
3.9% |
| Death |
3.1% |
| Renal Failure |
3.1% |
| Deep Vein Thrombosis |
2.9% |
| Febrile Neutropenia |
2.7% |
| Renal Failure Acute |
2.7% |
| Respiratory Distress |
2.7% |
| Toxic Skin Eruption |
2.6% |
| White Blood Cell Count Decreased |
2.6% |
|
| Interacting |
| Hypertension |
15.8% |
| Atrial Fibrillation |
11.6% |
| Bronchitis |
7.4% |
| Depression |
7.4% |
| Drug Use For Unknown Indication |
7.4% |
| Erysipelas |
6.3% |
| Lymphoma |
6.3% |
| Parkinson's Disease |
6.3% |
| Product Used For Unknown Indication |
5.3% |
| Arrhythmia |
4.2% |
| Thrombosis Prophylaxis |
4.2% |
| Bronchitis Chronic |
2.1% |
| Cardiomyopathy |
2.1% |
| Diabetes Mellitus |
2.1% |
| Lower Respiratory Tract Infection |
2.1% |
| Lung Disorder |
2.1% |
| Muscle Spasms |
2.1% |
| Sinusitis |
2.1% |
| Urinary Tract Infection |
2.1% |
| Angina Pectoris |
1.1% |
|
| International Normalised Ratio Increased |
26.7% |
| Labile Blood Pressure |
6.7% |
| Renal Failure |
6.7% |
| Vertigo |
6.7% |
| Wrong Drug Administered |
6.7% |
| Cardiac Disorder |
3.3% |
| Drug Interaction |
3.3% |
| Hypocoagulable State |
3.3% |
| Inflammation |
3.3% |
| Lower Respiratory Tract Infection |
3.3% |
| Melaena |
3.3% |
| Muscle Haemorrhage |
3.3% |
| Prothrombin Level Decreased |
3.3% |
| Rash Generalised |
3.3% |
| Rash Pruritic |
3.3% |
| Subdural Haematoma |
3.3% |
| Thirst |
3.3% |
| Vestibular Disorder |
3.3% |
| Weight Decreased |
3.3% |
|
